Antihypertensive treatment

4 papers7 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funder: National Natural Science Foundation of China

Human trial1

Outcomes

Mortality

downin humans1

1 study

Antihypertensive treatment decreases mortality in humans.
“shows a significant reduction in mortality and cardiovascular events by achieving a low blood pressure goal in patients over the age of 75 years old.”
Reviewachieving a low blood pressure goal
Hypertension in the elderly
Presse medicale (Paris, France : 1983)18 Jan 2019

Cardiovascular disease

downin humans1

1 study

Antihypertensive treatment decreases cardiovascular disease in humans.
“available evidence in individuals aged> 80 years seems to indicate that antihypertensive treatment results in a reduction of cardiovascular morbidity and mortality”
Review
Hypertension in older adults
Hipertension y riesgo vascular1 Jan 2017

Associations

Mild cognitive impairment

downin humans1

1 study

Antihypertensive treatment lowers the risk of mild cognitive impairment in humans (Log-rank P = 0.002).
“intensive/ePWV responders had the lowest risk of the primary outcome (Log-rank P = 0.002)”
Human trialintensive/ePWV responders12 monthsn = 8,563
Estimated Pulse Wave Velocity and Cognitive Outcomes: A Post hoc Analysis of SPRINT-MIND
American journal of hypertension14 Jun 2024